2025 Term Loan
On August 5, 2025, the Company entered into that certain financing agreement (the “Financing Agreement”), by and among the Company, as Parent Guarantor, the Company’s domestic subsidiaries party thereto as borrowers and guarantors, the lenders from time to time party thereto, and MGG Investment Group LP, as collateral agent and as administrative agent, pursuant to which the lenders agreed to advance the 2025 Term Loan. Proceeds from the 2025 Term Loan are expected to be approximately $72.9 million. The Company intends to use the proceeds from the 2025 Term Loan to retire all obligations and pay all related prepayment fees under its previously reported senior term loan, to retire certain of its obligations under certain legacy convertible subordinated promissory notes, to fund estimated transaction expenses and for general corporate purposes.
Obligations under the 2025 Term Loan will bear interest at variable rates set, at the Company’s option, based on a reference rate plus 7%, or the secured overnight financing rate as administered by the Federal Reserve Bank of New York (“SOFR”) plus 8%. Interest will be payable in cash monthly in arrears.
The principal amount of the 2025 Term Loan will be repayable in consecutive quarterly installments on the last business day of each March, June, September and December of each fiscal year commencing September 30, 2025, in an amount equal to (i) $468,750 with respect to each payment due on September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 and (ii) $937,500 with respect to each payment due thereafter, with the remaining principal amount due at the maturity of the 2025 Term Loan in July 2029 or such earlier time as it may become payable under the Financing Agreement. The Company also agreed to pay the lenders certain fees on a quarterly basis during the time the 2025 Term Loan remains outstanding, and an exit fee upon its maturity date or earlier termination.
The 2025 Term Loan may be prepaid by the Company starting in July 2027. In addition, the Financing Agreement will require prepayments of principal and accrued interest of the 2025 Term Loan upon the occurrence of certain events, including asset sales; receipt of proceeds from debt or equity financings; receipt of insurance payouts, tax refunds, judgments or other extraordinary events; as well as 50% of excess cash flow (as defined in the Financing Agreement) for any year, less any optional prepayments made by the Company in such fiscal year. Prepayments will be subject to certain fees set forth in the Financing Agreement, including the potential requirement to pay a make-whole or other premium upon amounts prepaid.
The 2025 Term Loan will rank senior to all other debt and will be secured by a first priority lien on substantially all of the Company’s assets. The Financing Agreement contains representations, warranties, covenants, terms and conditions customary for senior secured term loans of this type. These include covenants limiting the ability of the Company and its subsidiaries, subject to certain exceptions and baskets, to, among other things, (i) incur indebtedness, (ii) incur liens on their assets, (iii) enter into any transaction of merger, consolidation or amalgamation, liquidate, wind up or dissolve, or dispose of all or substantially all of their property or business, (iv) dispose of any of their property, or, issue or sell any shares of a subsidiary’s stock, (v) make any payment or prepayment for any subordinated indebtedness, pay any earn-out payment, seller debt or deferred purchase price payments, or (vi) declare or pay any dividend or make any other distribution. The representations, warranties and covenants contained in the Financing Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties therein, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Financing Agreement only provides investors with information regarding the terms of the Financing Agreement, and will not provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
The Financing Agreement also contains four financial covenants: a minimum cash balance requirement, a minimum ARR requirement, a minimum adjusted EBITDA requirement and a capital expenditure limitation.
The Financing Agreement contains certain events of default, including, among others, (i) failure to pay, (ii) breach of representations and warranties, (iii) breach of covenants, subject to any cure periods described therein, and (iv) failure to pay principal or interest on any other material debt. If any event of default occurs and is not cured within applicable grace periods set forth in the Financing Agreement or waived, all loans and other obligations could become due and immediately payable and the facility could be terminated. Upon the occurrence of a default, in addition to the lenders being able to declare amounts outstanding under the 2025 Term Loan due and payable, the lenders will be entitled to elect to increase the interest rate by 3% per annum.
The foregoing description of the Financing Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Financing Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.